The goal of this pilot, open-label prospective study is to evaluate if the effect of calcium channel blockade on plasma aldosterone levels in people with primary aldosteronism (PA) is due primarily to Cav1.3 blockade.
This will be tested by treating participants who have PA with both cinnarizine (Cav1.3 blocker) and nifedipine (Cav1.2 blocker) and evaluating effect on aldosterone levels and blood pressure over a two week course of treatment.

Start Date24 Apr 2023

Sponsor / Collaborator

Queen Mary University of London

IRCT20221108056444N1

/ RecruitingPhase 3IIT

Comparison of the effectiveness of Cinnarizine V/S Topiramate in migraine prophylaxis of children referred to pediatric neurology clinic

Start Date23 Sep 2022

Sponsor / Collaborator-

IRCT20110628006907N16

/ SuspendedPhase 3IIT

Interventional comparison of the effect of cinnarizine with placebo on mood swings and self-harm and stereotyped behaviors of autistic patients

Start Date20 Jan 2022

Sponsor / Collaborator

Tehran University of Medical Sciences

100 Clinical Results associated with Cinnarizine

100 Translational Medicine associated with Cinnarizine

100 Patents (Medical) associated with Cinnarizine

1,283

Literatures (Medical) associated with Cinnarizine

31 Dec 2025·Channels

Sclareol and cinnarizine are non-selective inhibitors of voltage-gated Cav1.3 L-type Ca ²⁺ channels

Article

Author: Leitzbach, Luisa ; Zanetti, Lucia ; Stark, Holger ; Török, Ferenc ; Striessnig, Jörg

A growing body of preclinical evidence indicates that the inhibition of voltage-gated Cav1.3 L-type Ca²⁺ channels could be a therapeutic concept for the therapy of treatment-resistant hypertension, spinal injury and for neuroprotection in early Parkinson's disease (PD). However, available Ca²⁺-channel blockers are potent inhibitors of vascular Cav1.2 L-type channels which can cause low blood pressure as an adverse drug reaction. Therefore, Cav1.3-selective inhibitors are needed to further investigate the therapeutic potential of Cav1.3 as drug target in vivo. The bicyclic diterpene alcohol sclareol has recently been reported to exert neuroprotective properties in a mouse PD model by blocking Cav1.3 L-type channels. This study investigates the proposed Cav1.3-selectivity of sclareol compared to Cav1.2 and to other voltage-gated Ca²⁺ channels in whole-cell patch-clamp experiments. Various stimulation protocols, including dopamine neuron-like firing patterns show that sclareol is neither a subtype-selective nor a potent blocker of heterologously expressed Cav1.3 and inhibits also Cav2.3 channels. Therefore, the contribution of Cav1.3 channel inhibition for the previously reported neuroprotective effects of sclareol in a mouse PD model remains unclear. In addition, cinnarizine, a vertigo therapeutic also under investigation for inhibition of Cav1.3-mediated aldosterone-secretion, inhibits Cav1.3 channels in a frequency-dependent manner, but also without relevant selectivity with respect to Cav1.3.

10 Oct 2025·ACS Infectious Diseases

Structural Exploitation of Cinnarizine Identified Novel Drug-Like Anthelmintic Agents Against Angiostrongylus cantonensis

Article

Author: Fernandes, João Paulo S. ; Lopes, Flavia B. ; Motta, Natalia E. P. ; Silva, Aline S. ; Siegl-Breno, Mariana A. ; Lemes, Bruna L. ; Silva-Nunes, Mikaelly K. ; de Moraes, Josué

The impact of helminthiases on global health for both humans and animals and the limited efficacy of existing drugs against these infections reinforces the urgent need for novel anthelmintic agents. On this background, in previous work we identified cinnarizine, a first-generation antihistamine, as effective anthelmintic agent against Angiostrongylus cantonensis first-stage larvae (L1) in vitro. A. cantonensis worm is the causative agent of neuroangiostrongyliasis, a condition that leads to eosinophilic meningitis with no effective treatment to date. In the present work, modifications on cinnarizine structure were designed to improve its efficacy against the larvae but keeping its ability to cross the blood brain barrier allied to improvement in the drug-like and solubility profile. A set of 11 compounds were synthesized and tested against L1 larvae, showing EC₅₀ values ranging from 9.3 to 4.2 μM. The most effective were also tested against infective third-stage larvae (L3), with EC₅₀ 18.1-8.6 μM. None of the compounds showed toxicity to both HaCat mammalian cells (at 500 μM) and Caenorhabditis elegans (at 1000 μM), indicating their high selective toxicity toward A. cantonensis. Structure-activity relationship analysis using molecular descriptors indicated that presence of two basic nitrogen atoms and balanced lipophilicity of compound 2b (EC₅₀ L1 9.3 μM; L3 8.8 μM) played the role in the anthelmintic activity, and simplified compound 3a (EC₅₀ L1 8.7 μM; L3 18.1 μM) represent a novel prototype for further modifications.

06 Oct 2025·MOLECULAR PHARMACEUTICS

A Comparative Study of Flash Nanoprecipitation and Sequential Nanoprecipitation: Impact of Formulation Parameters on Drug-Loaded Nanoparticle Formation

Article

Author: Pinkerton, Nathalie M. ; Lewis, Parker K. ; El Amri, Nouha ; McKinstry, Amy ; Pollard, Rachel E.

Flash NanoPrecipitation (FNP) is a well-established method for forming core-shell drug-loaded nanoparticles that has demonstrated effectiveness for encapsulating highly hydrophobic compounds. However, certain formulation challenges persist, including size limitations and reduced encapsulation efficiency for moderately hydrophobic drugs. Sequential NanoPrecipitation (SNaP) is a novel nanoparticle synthesis process that relies on the same assembly principle as FNP, while decoupling the core formation and stabilization. Through a systematic comparison using drugs with varying hydrophobicity, we demonstrate complementary capabilities between these techniques. We showed that for the high hydrophobicity drugs such as β-carotene, both SNaP and FNP performed effectively. In the case of cinnarizine, a moderately hydrophobic drug that requires the use of hydrophobic ion pairing, good encapsulation efficiency was observed for the case of SNaP, while no encapsulation was observed with FNP. For ibuprofen, a water-soluble analgesic, low encapsulation efficiency was observed with SNaP, and no loading was observed with FNP. Release studies with itraconazole nanoparticles revealed that SNaP-produced nanoparticles exhibited approximately 50% slower release rates compared to FNP over 48 h. Additionally, SNaP enabled access to a broader size range and successful nanoparticle formation at lower solid concentrations. These findings establish SNaP as a valuable complement to FNP, particularly for applications requiring larger nanoparticles, encapsulation of moderately hydrophobic compounds, or modified release kinetics. Together, these nanoprecipitation approaches provide formulators with expanded capabilities for developing polymeric nanoparticle drug delivery systems.

News (Medical) associated with Cinnarizine

11 Sep 2025

·pharma.economictimes.indiatimes.com

Dr Reddy’s acquires J&J CNS brands 18 market rights for over $50 million

Hyderabad: Indian pharma major, Dr Reddy’s Laboratories has announced the acquisition of Johnson and Johnson (J&J) anti-vertigo therapy ‘ Stugeron ’ and its local brands 18 market rights for $50.5 million (nearly Rs 445 crore). In a stock exchange filing the company informed that it has a definitive agreement with Janssen Pharmaceutica Janssen Pharmaceutica NV, a subsidiary of J&J to "acquire a Central Nervous System (CNS) brand Stugeron along with its locally recognized brands– Forte, Stugeron Plus—18 market s including India for a one time consideration of $50.5 million." “Dr. Reddy’s acquisition of the Stugeron brand reflects a steady advancement in our efforts to expand into the anti-vertigo therapeutic segment, contributing to the continued development of our CNS portfolio,” said M.V. Ramana, CEO, India and Emerging Markets, Dr. Reddy's Laboratories. The multi-market commercial deal gives Dr Reddy’s access to over 18 markets in the Asia-Pacific and Middle East commercial rights and the Indian drugmaker has stated to “initiate operations to ensure smooth integration of the business.” Stugeron developed from the active ingredient ‘ Cinnarizine ’ is an antihistamine medicine, indicated to prevent and treat dizziness, nausea, vomiting, headaches, associated with motion sickness and vertigo. The drug is a calcium channel blocker which reduces activity in the inner ear and helps control the feeling of dizziness and spinning. It also blocks histamine, a natural substance in the body that can cause nausea and vomiting. Stugeron’s active ingredient is small molecule that has lost its patent exclusivity across several markets including India, However the US drugmaker brand is stated to be the second biggest brand in the anti-vertigo extended represented pharmaceutical market (eRPM) in India In India, the brand is in a direct contest with Cipla’s Vertiron , FDC’s Cinzan , and Mankind’s Dizikind —as all of them operate on the same dosage strength. Notably, Dr Reddy’s is one of India's leading CNS API manufacturer which produces ingredients like Atomoxetine Hydrochloride, Benztropine Mesylate etc. and operates across several subgroups including Bipolar Mood Disorders (BMD), Major Depressive Disorders (MDD), ADHD, Epilepsy, Alzheimer's etc. By Online Bureau ,

Acquisition

100 Deals associated with Cinnarizine

External Link

KEGG	Wiki	ATC	Drug Bank
D01295	Cinnarizine	N07CA02	DB00568

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cerebrovascular Disorders	-	-	-
Vertigo	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis